Viking Therapeutics (VKTX) Tops Q4 EPS by 3c

Viking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($0.07), $0.03 better than the analyst estimate of ($0.10).

"The past year has been a transformative period for Viking, and we are excited to continue this momentum in 2019," stated Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. "We were particularly pleased in 2018 to have presented positive Phase 2 data from our novel thyroid receptor beta agonist VK2809 in non-alcoholic fatty liver disease at the AASLD conference, and honored that these results were featured in the Best of AASLD conference highlights. We plan to present additional, new results from this study at the upcoming EASL conference in April, and remain on-track to file an IND to initiate a study in biopsy-confirmed NASH later this year. In addition, pre-IND work for our second thyroid receptor agonist VK0214 continues to progress, and we plan to file an IND to initiate clinical development by the end of the year. Thanks to successful fundraising efforts in 2018, we ended the year with more than $300 million on our balance sheet, and are now capitalized to reach major inflection points for multiple programs. Entering 2019, we are focused on executing our operating plans and enthusiastic about the future development of our pipeline."

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• More trouble for SpaceX? Analyst flags robotics and space as key bubble risk areas
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat